Celsense

 

 

NEWS RELEASE - For Immediate Release

Celsense, Inc. to Give Company Presentation at the Stem Cell Meeting on the Mesa

October 3, 2013 - Pittsburgh, Pennsylvania

Dr. Eric T. Ahrens, the founder of Celsense and the inventor of the Celsense technologies, will give a company presentation on Monday October 14, 2013 at the 3rd Annual Regenerative Medicine Partnering Forum, part of the Stem Cell Meeting on the Mesa to be held October 14-16 in La Jolla, CA.

Organized by the Alliance for Regenerative Medicine (ARM), the California Institute for Regenerative Medicine (CIRM) and the Sanford Consortium for Regenerative Medicine, the 2013 Stem Cell Meeting on the Mesa is a three-day conference aimed at bringing together senior members of the regenerative medicine industry with the scientific research community to advance stem cell science into cures. The Regenerative Medicine Partnering Forum, held October 14 &15 at the Estancia La Jolla Hotel, is the only partnering meeting organized specifically for the regenerative medicine and advanced therapies industry.

The meeting also features a nationally recognized Scientific Symposium, held October 16 at the Salk Institute for Biological Studies, showcasing leading academic research in the field of regenerative medicine. Combined, these meetings attract over 800 attendees from around the globe, fostering key partnerships through one-on-one meetings while also highlighting clinical and commercial progress in the field.

A live video webcast of all company presentations will be available at: http://stemcellmeetingonthemesa.com/webcast/ and will also be published on ARM’s website shortly after the event.

Please visit http://stemcellmeetingonthemesa.com/ for full information including registration. Complimentary attendance at this event is available for credentialed investors and members of the media only. Investors and media should contact Laura Parsons at lparsons@alliancerm.org.

About Celsense, Inc.
Celsense, Inc. develops and offers novel pre-clinical and clinical-grade products that enable the non-invasive imaging of cells in vivo using MRI. The company’s lead product Cell Sense is a patented fluorocarbon tracer agent used to safely and efficiently label cells ex vivo without the use of transfection agents. Cell Sense is the subject of a Drug Master File at US FDA and Health Canada, and is the only clinical grade MRI cell tracking reagent available in North America. Using software developed by Celsense, investigators can quantify the number of labeled cells in a user-specified region of interest. Celsenses mission is to be the standard for cellular imaging in human health.

Contact Information:

Charlie O’Hanlon, President and CEO
Celsense, Inc.
(412) 263-2870
charlie@celsense.com